Clinical Trial Update: A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating BL-B01D1 in combination with a PD-1 inhibitor for locally advanced or metastatic urothelial carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• BL-B01D1
• PD-1

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Urothelial Carcinoma | Phase 2 | Status: RECRUITING